Aprea Therapeutics, Inc.
APRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $0 | $0 |
| % Growth | 157.6% | – | – | – |
| Cost of Goods Sold | $9 | $0 | $16 | $0 |
| Gross Profit | -$8 | $1 | -$16 | -$0 |
| % Margin | -523.2% | 98.8% | – | – |
| R&D Expenses | $9 | $8 | $92 | $24 |
| G&A Expenses | $6 | $8 | $21 | $14 |
| SG&A Expenses | $6 | $8 | $21 | $14 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | -$9 | $0 | -$16 | -$0 |
| Operating Expenses | $6 | $16 | $97 | $37 |
| Operating Income | -$14 | -$15 | -$113 | -$37 |
| % Margin | -953% | -2,652.8% | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $0 |
| Pre-Tax Income | -$13 | -$14 | -$113 | -$37 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13 | -$14 | -$113 | -$37 |
| % Margin | -862.4% | -2,449.6% | – | – |
| EPS | -2.35 | -3.95 | -1,359.79 | -34.88 |
| % Growth | 40.5% | 99.7% | -3,798.5% | – |
| EPS Diluted | -2.35 | -3.95 | -1,359.79 | -34.88 |
| Weighted Avg Shares Out | 6 | 4 | 0 | 1 |
| Weighted Avg Shares Out Dil | 6 | 4 | 0 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$14 | -$14 | -$37 | -$37 |
| % Margin | -951.5% | -2,448.4% | – | – |